David Westenberg
Stock Analyst at Piper Sandler
(3.54)
# 730
Out of 4,814 analysts
164
Total ratings
42.27%
Success rate
5.76%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKYA Akoya Biosciences | Maintains: Neutral | $2.4 → $1.65 | $1.10 | +50.00% | 8 | Apr 14, 2025 | |
| NEOG Neogen | Maintains: Neutral | $13 → $6.5 | $4.39 | +48.06% | 11 | Apr 14, 2025 | |
| ELAN Elanco Animal Health | Maintains: Neutral | $16 → $12 | $8.44 | +42.18% | 9 | Mar 6, 2025 | |
| TEM Tempus AI | Maintains: Neutral | $70 → $55 | $40.45 | +35.97% | 3 | Mar 4, 2025 | |
| NTRA Natera | Maintains: Overweight | $200 → $205 | $148.08 | +38.44% | 14 | Mar 4, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $22 → $16 | $17.86 | -10.39% | 7 | Mar 4, 2025 | |
| CTKB Cytek Biosciences | Maintains: Overweight | $8.5 → $8 | $3.66 | +118.88% | 9 | Mar 4, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $200 → $205 | $148.66 | +37.90% | 13 | Feb 27, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $21 → $18 | $9.54 | +88.68% | 8 | Feb 26, 2025 | |
| GH Guardant Health | Maintains: Overweight | $34 → $50 | $45.18 | +10.67% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $41.59 | +68.33% | 10 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2.5 → $2 | $1.17 | +70.94% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $11 | $7.33 | +50.17% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $260 | $217.06 | +19.79% | 3 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $185 → $190 | $71.16 | +167.00% | 15 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $435 → $510 | $411.55 | +23.92% | 10 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $165 → $180 | $163.77 | +9.91% | 6 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.84 | +5.63% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $7.51 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $25.15 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $34.72 | - | 1 | Nov 21, 2017 |
Akoya Biosciences
Apr 14, 2025
Maintains: Neutral
Price Target: $2.4 → $1.65
Current: $1.10
Upside: +50.00%
Neogen
Apr 14, 2025
Maintains: Neutral
Price Target: $13 → $6.5
Current: $4.39
Upside: +48.06%
Elanco Animal Health
Mar 6, 2025
Maintains: Neutral
Price Target: $16 → $12
Current: $8.44
Upside: +42.18%
Tempus AI
Mar 4, 2025
Maintains: Neutral
Price Target: $70 → $55
Current: $40.45
Upside: +35.97%
Natera
Mar 4, 2025
Maintains: Overweight
Price Target: $200 → $205
Current: $148.08
Upside: +38.44%
Fulgent Genetics
Mar 4, 2025
Maintains: Neutral
Price Target: $22 → $16
Current: $17.86
Upside: -10.39%
Cytek Biosciences
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $3.66
Upside: +118.88%
Zoetis
Feb 27, 2025
Maintains: Overweight
Price Target: $200 → $205
Current: $148.66
Upside: +37.90%
NeoGenomics
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $9.54
Upside: +88.68%
Guardant Health
Feb 26, 2025
Maintains: Overweight
Price Target: $34 → $50
Current: $45.18
Upside: +10.67%
Feb 26, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $41.59
Upside: +68.33%
Feb 20, 2025
Reiterates: Neutral
Price Target: $2.5 → $2
Current: $1.17
Upside: +70.94%
Feb 20, 2025
Reiterates: Overweight
Price Target: $7 → $11
Current: $7.33
Upside: +50.17%
Feb 10, 2025
Maintains: Neutral
Price Target: $240 → $260
Current: $217.06
Upside: +19.79%
Feb 10, 2025
Maintains: Overweight
Price Target: $185 → $190
Current: $71.16
Upside: +167.00%
Feb 10, 2025
Maintains: Neutral
Price Target: $435 → $510
Current: $411.55
Upside: +23.92%
Feb 3, 2025
Reiterates: Neutral
Price Target: $165 → $180
Current: $163.77
Upside: +9.91%
Nov 13, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.84
Upside: +5.63%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $7.51
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $25.15
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $34.72
Upside: -